Curcumin and Retinal Study
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age40-89
SponsorTexas Tech University Health Sciences Center
About this trial
To test how two weeks of curcumin supplementation would cross the blood brain barrier (BBB) and attach to amyloid beta proteins, to assess the feasibility (safety and bioavailability), and to explore the resulting abundance/composition of gut microbiota.
Eligibility criteria
Qualifiers
Both male and female, age 40 - 89 years.
Diagnosed with Aβ deposits in retina (peripheral superior quadrants)--to be confirmed after consent obtained. If there is documentation the potential participant has been diagnosed with Aβ deposits in retina within 6 months before the consent session, we will use this diagnosis/documentation for eligibility criteria. Otherwise, the ophthalmic exam will be repeated after consent is obtained for the study.
No pre-existing liver or kidney diseases by self-report.
Patients with ocular diseases (macular degeneration, severe diabetes retinopathy)
Disqualifiers
None
Trial design
Treatments tested in this trial
- Low curcumin group
- High curcumin group
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov